Latest Production Development News

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.

Integrated Research Limited reported an 18% revenue decline and a 51% drop in net profit for FY25, while unveiling a strategic pivot towards AI-driven product innovation and cloud services.

Austco Healthcare has reported a robust FY25 with revenues climbing 40% to $81.4 million and EBITDA jumping 62% to $13 million, driven by organic growth and strategic acquisitions.

Austco Healthcare Limited reported a record $81.4 million in revenue for FY25, driven by organic growth and acquisitions including G&S Technologies. EBITDA jumped 62% to $13 million, reflecting strong operational leverage.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Activeport Group has successfully closed a fully underwritten rights issue, raising approximately $2.5 million to support its telecommunications software ambitions. The offer included free attaching options, signaling confidence in future growth.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

PolyNovo Limited reported a robust 28.9% increase in group sales to A$118.6 million for FY25, alongside a 151% surge in net profit after tax to A$13.2 million, driven by strong U.S. growth and key regulatory approvals.